<DOC>
	<DOCNO>NCT01860560</DOCNO>
	<brief_summary>Order randomize crossover non-inferiority study evaluate acute efficacy High Flow Therapy ( HFT ) compare nasal Continuous Positive Airway Pressure therapy ( CPAP ) management apnea / hypopnea index ( AHI ) .</brief_summary>
	<brief_title>Non-Inferiority Trial Acute HFT Versus nCPAP</brief_title>
	<detailed_description>Study evaluate acute efficacy single night High Flow Therapy ( HFT ) treat mild-moderate predominantly obstructive Sleep Disordered Breathing , compare nasal Continuous Positive Airway Pressure ( CPAP ) therapy . Subjects order-randomized receive HFT CPAP laboratory , undergo washout period , return alternative therapy laboratory . The hypothesis HFT non-inferior CPAP control Apnea/Hypopnea event subject set study . Primary outcome Apnea / Hypopnea Index ( AHI ) change therapy compare baseline diagnostic polysomnography .</detailed_description>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<criteria>At least 18 year age Previous diagnosis primarily obstructive mildmoderate Sleep Disordered Breathing inlaboratory polysomnography Ability read understand English Language Ability provide inform consent Unstable medical illness within last month ( 30 day ) Acute / recent upper airway infection Prior use noncontinuous positive airway pressure medical technology therapy prescribe physician management obstructive sleep disorder breathing ( e.g. , Provent® , Winx™ , mandibular advancement oral appliance , etc . ) Prior use exposure CPAP / BiLevel / noninvasive ventilatory modality Craniofacial anatomical anomaly may predispose patient upper airway obstruction , obvious blockage nasal air flow Patients use opioids amphetamine exclude study . Enhanced oxygen requirement ( i.e. , FiO2 &gt; 0.21 ) Patients require BiLevel therapy upon CPAP titration attempt Surgery since diagnostic PSG Significant recent sedative/hypnotic use likely , opinion principle investigator , impair ventilatory control impact subsequent titration either CPAP therapy Flowrest therapy ( include benzodiazepine , antihistamine , imidazopyridines ) Significant use stimulant medication likely , opinion principle investigator , likely alter ventilatory upper airway control impact subsequent titration either CPAP therapy Flowrest therapy ( include amphetamine , high dose caffeine , etc . ) Significant neurologic cardiac pathology likely seriously impact respiratory effort ventilatory control ( e.g. , post CVA ventilatory impairment ) Presence significant sleep disorder likely induce hypersomnolence interfere ability titrate CPAP therapy Flowrest therapy ( include narcolepsy , PLMS/RLS , severe chronic insomnia , nonOSA obesity hypoventilation syndrome , etc . ) Unsuitable inclusion opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>OSA</keyword>
	<keyword>Obstructive Sleep Apnea</keyword>
	<keyword>High Flow Therapy</keyword>
	<keyword>CPAP</keyword>
	<keyword>HFT</keyword>
	<keyword>Continuous Positive Airway Pressure</keyword>
	<keyword>Mild OSA</keyword>
	<keyword>Moderate OSA</keyword>
</DOC>